▶ 調査レポート

脳卒中治療の世界市場:種類別、薬物クラス別、流通チャンネル別

• 英文タイトル:Stroke Treatment Market (Type: Ischemic Stroke and Hemorrhagic Stroke; Drug Class: Tissue Plasminogen Activators (tPA), Anticoagulants, Antiplatelets, Anticonvulsants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Stroke Treatment Market (Type: Ischemic Stroke and Hemorrhagic Stroke; Drug Class: Tissue Plasminogen Activators (tPA), Anticoagulants, Antiplatelets, Anticonvulsants, Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027「脳卒中治療の世界市場:種類別、薬物クラス別、流通チャンネル別」(市場規模、市場予測)調査レポートです。• レポートコード:TPM-NV161
• 出版社/出版日:Transparency Market Research / 2019年10月
• レポート形態:英文、PDF、171ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥799,710 (USD5,795)▷ お問い合わせ
  Multi User¥1,213,710 (USD8,795)▷ お問い合わせ
  Global Site License¥1,627,710 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、脳卒中治療の世界市場について調べ、脳卒中治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、種類別(虚血性脳卒中および出血性脳卒中)分析、薬物クラス別(組織プラスミノーゲン活性化因子(tPA)、抗凝固薬、抗血小板薬、抗痙攣薬、その他)分析、流通チャンネル別(病院薬局、小売薬局、オンライン薬局)分析、関連企業情報などをまとめました。
・脳卒中治療の市場概要
・脳卒中治療の市場動向
・脳卒中治療の世界市場規模・予測
・脳卒中治療市場:種類別(虚血性脳卒中および出血性脳卒中)
・脳卒中治療市場:薬物クラス別(組織プラスミノーゲン活性化因子(tPA)、抗凝固薬、抗血小板薬、抗痙攣薬、その他)
・脳卒中治療市場:薬物クラス別(組織プラスミノーゲン活性化因子(tPA)、抗凝固薬、抗血小板薬、抗痙攣薬、その他)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

Healthcare providers are recommending the consumption of non-vitamin K oral anticoagulants over commercially available medications such as Warfarin to reduce the incidence of atrial fibrillation in the stroke treatment market space. These efficacious oral anticoagulants are increasingly catching the attention of consumers and healthcare providers, as they effectively minimize the formation of clots in the blood. This is validated, as the revenue of anticoagulants amongst all drugs in the stroke treatment market is projected to hold the second-highest position, with a value of ~US$ 4.2 billion by 2027.

Oral anticoagulants are serving the convenience of stroke patients, as they can regularize any potential symptoms in home care settings. Thus, new oral anticoagulants are creating incremental opportunities for hospital, retail, and online pharmacies, as users can request for bulk orders at any given time. Healthcare companies in the stroke treatment market are developing improved formulations that make anticoagulants safer and help in reducing the risk of internal bleeding.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Stroke Treatment Market

4. Market Overview

4.1. Introduction

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Stroke Treatment Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

5.1. Key Industry Developments

5.2. Pipeline Analysis

5.3. Epidemiology Analysis

6. Global Stroke Treatment Market Value and Forecast, by Type

6.1. Introduction & Definition

6.2. Global Stroke Treatment Market Value Forecast, by Type, 2017–2027

6.2.1. Ischemic Stroke

6.2.2. Hemorrhagic Stroke

6.3. Global Stroke Treatment Market Attractiveness, by Type

7. Global Stroke Treatment Market Value and Forecast, by Drug Class

7.1. Introduction & Definition

7.2. Global Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

7.2.1. Tissue Plasminogen Activator (tPA)

7.2.2. Anticoagulants

7.2.3. Antiplatelets

7.2.4. Anticonvulsants

7.2.5. Others

7.3. Global Stroke Treatment Market Attractiveness, by Drug Class

8. Global Stroke Treatment Market Value and Forecast, by Distribution Channel

8.1. Introduction

8.2. Global Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

8.2.1. Hospital Pharmacies

8.2.2. Retail Pharmacies

8.2.3. Online Pharmacies

8.3. Global Stroke Treatment Market Attractiveness, by Distribution Channel

9. Global Stroke Treatment Market Value and Forecast, by Region

9.1. Introduction

9.2. Stroke Treatment Market Value Forecast, by Region, 2017–2027

9.2.1. North America

9.2.2. Europe

9.2.3. Asia Pacific

9.2.4. Latin America

9.2.5. Middle East & Africa

9.3. Global Stroke treatment Market Attractiveness, by Region

10. North America Stroke Treatment Market Analysis and Forecast

10.1. Introduction

10.2. North America Stroke Treatment Market Value Forecast, by Type, 2017–2027

10.2.1. Ischemic Stroke

10.2.2. Hemorrhagic Stroke

10.3. North America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

10.3.1. Tissue Plasminogen Activator (tPA)

10.3.2. Anticoagulants

10.3.3. Antiplatelets

10.3.4. Anticonvulsants

10.3.5. Others

10.4. North America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Online Pharmacies

10.5. North America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. North America Stroke treatment Market Attractiveness Analysis

10.6.1. By Type

10.6.2. By Drug Class

10.6.3. By Distribution Channel

10.6.4. By Country

11. Europe Stroke Treatment Market Analysis and Forecast

11.1. Introduction

11.2. Europe Stroke Treatment Market Value Forecast, by Type, 2017–2027

11.2.1. Ischemic Stroke

11.2.2. Hemorrhagic Stroke

11.3. Europe Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

11.3.1. Tissue Plasminogen Activator (tPA)

11.3.2. Anticoagulants

11.3.3. Antiplatelets

11.3.4. Anticonvulsants

11.3.5. Others

11.4. Europe Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Online Pharmacies

11.5. Europe Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Europe Stroke treatment Market Attractiveness Analysis

11.6.1. By Type

11.6.2. By Drug Class

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Asia Pacific Stroke Treatment Market Analysis and Forecast

12.1. Introduction

12.2. Asia Pacific Stroke Treatment Market Value Forecast, by Type, 2017–2027

12.2.1. Ischemic Stroke

12.2.2. Hemorrhagic Stroke

12.3. Asia Pacific Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

12.3.1. Tissue Plasminogen Activator (tPA)

12.3.2. Anticoagulants

12.3.3. Antiplatelets

12.3.4. Anticonvulsants

12.3.5. Others

12.4. Asia Pacific Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Online Pharmacies

12.5. Asia Pacific Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

12.5.1. Japan

12.5.2. China

12.5.3. India

12.5.4. Australia & New Zealand

12.5.5. Rest of Asia Pacific

12.6. Asia Pacific Stroke treatment Market Attractiveness Analysis

12.6.1. By Type

12.6.2. By Drug Class

12.6.3. By Distribution Channel

12.6.4. By Country/Sub-region

13. Latin America Stroke Treatment Market Analysis and Forecast

13.1. Introduction

13.2. Latin America Stroke Treatment Market Value Forecast, by Type, 2017–2027

13.2.1. Ischemic Stroke

13.2.2. Hemorrhagic Stroke

13.3. Latin America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

13.3.1. Tissue Plasminogen Activator (tPA)

13.3.2. Anticoagulants

13.3.3. Antiplatelets

13.3.4. Anticonvulsants

13.3.5. Others

13.4. Latin America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

13.4.1. Hospital Pharmacies

13.4.2. Retail Pharmacies

13.4.3. Online Pharmacies

13.5. Latin America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

13.5.1. Brazil

13.5.2. Mexico

13.5.3. Rest of Latin America

13.6. Latin America Stroke treatment Market Attractiveness Analysis

13.6.1. By Type

13.6.2. By Drug Class

13.6.3. By Distribution Channel

13.6.4. By Country/Sub-region

14. Middle East & Africa Stroke treatment Market Analysis and Forecast

14.1. Introduction

14.2. Middle East & Africa Stroke Treatment Market Value Forecast, by Type, 2017–2027

14.2.1. Ischemic Stroke

14.2.2. Hemorrhagic Stroke

14.3. Middle East & Africa Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027

14.3.1. Tissue Plasminogen Activator (tPA)

14.3.2. Anticoagulants

14.3.3. Antiplatelets

14.3.4. Anticonvulsants

14.3.5. Others

14.4. Middle East & Africa Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027

14.4.1. Hospital Pharmacies

14.4.2. Retail Pharmacies

14.4.3. Online Pharmacies

14.5. Middle East & Africa Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027

14.5.1. GCC Countries

14.5.2. South Africa

14.5.3. Rest of Middle East & Africa

14.6. Middle East & Africa Stroke treatment Market Attractiveness Analysis

14.6.1. By Type

14.6.2. By Drug Class

14.6.3. By Distribution Channel

14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Global Stroke Treatment Market Position Analysis, by Company, 2018

15.2. Company Profiles

15.2.1. Bristol-Myers Squibb Company

15.2.1.1. Company Description

15.2.1.2. Business Overview

15.2.1.3. Financial Overview

15.2.1.4. Strategic Overview

15.2.1.5. SWOT Analysis

15.2.2. Boehringer Ingelheim GmbH

15.2.2.1. Company Description

15.2.2.2. Business Overview

15.2.2.3. Financial Overview

15.2.2.4. Strategic Overview

15.2.2.5. SWOT Analysis

15.2.3. Daiichi Sankyo Company, Limited

15.2.3.1. Company Description

15.2.3.2. Business Overview

15.2.3.3. Financial Overview

15.2.3.4. Strategic Overview

15.2.3.5. SWOT Analysis

15.2.4. F. Hoffmann-La Roche Ltd

15.2.4.1. Company Description

15.2.4.2. Business Overview

15.2.4.3. Financial Overview

15.2.4.4. Strategic Overview

15.2.4.5. SWOT Analysis

15.2.5. Johnson & Johnson Services, Inc.

15.2.5.1. Company Description

15.2.5.2. Business Overview

15.2.5.3. Financial Overview

15.2.5.4. Strategic Overview

15.2.5.5. SWOT Analysis

15.2.6. Sanofi

15.2.6.1. Company Description

15.2.6.2. Business Overview

15.2.6.3. Financial Overview

15.2.6.4. Strategic Overview

15.2.6.5. SWOT Analysis

15.2.7. Amgen, Inc.

15.2.7.1. Company Description

15.2.7.2. Business Overview

15.2.7.3. Financial Overview

15.2.7.4. Strategic Overview

15.2.7.5. SWOT Analysis

15.2.8. Biogen Inc.

15.2.8.1. Company Description

15.2.8.2. Business Overview

15.2.8.3. Financial Overview

15.2.8.4. Strategic Overview

15.2.8.5. SWOT Analysis

15.2.9. AstraZeneca

15.2.9.1. Company Description

15.2.9.2. Business Overview

15.2.9.3. Financial Overview

15.2.9.4. Strategic Overview

15.2.9.5. SWOT Analysis